Maternal anti-Toxoplasma Treatment during Pregnancy is Associated with Reduced Sensitivity of Diagnostic Tests for Congenital Infection in the Neonate - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Microbiology Année : 2021

Maternal anti-Toxoplasma Treatment during Pregnancy is Associated with Reduced Sensitivity of Diagnostic Tests for Congenital Infection in the Neonate

Résumé

Neonatal diagnosis of congenital toxoplasmosis is based on a combination of serological and molecular tests. Maternal screening and treatment differ according to national policies and may impact the sensitivity of diagnostic methods in infants at birth. In this multicenter study, 115 neonates born to 61 treated (53%) and 54 (47%) untreated women were retrospectively included in three centers (France, Serbia, and the United States) to assess the impact of maternal anti- treatment on the performance of neonatal workup at birth (neosynthesized anti- IgM, IgA, and IgG and quantitative PCR [qPCR]) using univariate and multivariate approaches. Independently of the time of maternal seroconversion, the serological techniques were impacted differently by maternal treatment. The detection of IgM by immunosorbent agglutination assay (ISAGA) and Western blotting (WB) dropped from 90.7% and 88.2% in untreated neonates to 53.3% and 51.9% in treated neonates ( < 0.05), whereas IgM enzyme-linked immunosorbent assay (ELISA) and IgA ISAGA were not significantly affected by maternal treatment. A 2-fold reduction in the sensitivity of neosynthesized IgG by WB was also observed in the case of treatment during pregnancy (37.7% versus 82.3%). Interestingly, the effect of treatment was shown to be duration dependent, especially for IgM detection, when the treatment course exceeded 8 weeks, whatever the therapy. The sensitivity of PCR in blood was also lowered by maternal treatment from 39.1% to 23.2%. These results highlight that anti- therapy during pregnancy may set back biological evidence of neonatal infection at birth and underline the need for a careful serological follow-up of infants with normal workup.
Fichier principal
Vignette du fichier
Guegan_et_al_2020-Maternal_anti-Toxoplasma_Treatment_accepted.pdf (1.02 Mo) Télécharger le fichier
Guegan_et_al_2020-Maternal_anti-Toxoplasma_Treatment_suppl_data.pdf (477.93 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03040797 , version 1 (15-12-2020)

Identifiants

Citer

Hélène Guegan, Tijana Stajner, Branko Bobić, Cindy Press, Rares T Olariu, et al.. Maternal anti-Toxoplasma Treatment during Pregnancy is Associated with Reduced Sensitivity of Diagnostic Tests for Congenital Infection in the Neonate. Journal of Clinical Microbiology, 2021, 59 (2), ⟨10.1128/JCM.01368-20⟩. ⟨hal-03040797⟩
67 Consultations
116 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More